Altria Group, Inc. · NYSE:MO
Altria — 74th Tobacco Science Research Conference 2021
22 slides from Altria's conference presentation, Aug 31, 2021
Slide 1: The Path Forward on Harm Reduction
THE PATH FORWARD ON HARM REDUCTION Maria Gogova, M.D., Ph.D. Vice President & Chief Scientific Officer for Altria Client Services 74TH TOBACCO SCIENCE RESEARCH CONFERENCE Altria Client Services
Slide 2: Right Now: 33,000,000+ US adult smokers
33,000,000+ US adult smokers Half may be interested in lower risk alternatives RIGHT NOW Any path forward on harm reduction CANNOT LEAVE THEM BEHIND Source: Altria Client Services LLC Adult Tobacco Consumer Tracker (ALCS ATCT) Age 21 or older 2
Slide 3: Continuum of risk for nicotine delivery
We must acknowledge that there’s a continuum of risk for nicotine delivery. That continuum ranges from combustible cigarettes at one end, to medicinal nicotine products at the other. – Former FDA Commissioner Gottlieb https://www.fda.gov/news-events/speeches-fda-officials/protecting-american-familie
Slide 4: Manufacturers must scientifically demonstrate harm reduction
CONGRESS: Manufacturers must scientifically demonstrate harm reduction 4
Slide 5: SRNT Society News
@ SRNT Society News Dear Colleagues, Dear Colleagues, ‘commercial tobacco produets; manutactuter. Ayo ave emo As part of our recent SRNT 2025 strategic planning initiative, the Board of Directors has been htt tesaill carefully reviewing our policies regarding participation in Society-sponsored event
Slide 6: AJPH paper by past SRNT presidents
AJPH Home » American Journal of Public Health (AJPH) » First Look David J. K. Balfour DSc, Neal L. Benowitz MD, Suzanne M. Colby PhD, Dorothy K. Hatsukami PHD, Scott J. Leischow Caryn Lerman... (show all authors) [+] Author affiliations, informa correspondence details Accepted: May 15, 2 THE NATIONA
Slide 7: Path Forward
PATH FORWARD Each stakeholder fulfilling their role in a system that fairly explores the science of tobacco harm reduction from all interested parties and supports a rigorous product scrutiny by FDA to responsibly shape the adult consumer marketplace 7
Slide 8: Smoke-Free Future
Responsibly lead the transition of adult smokers to a SMOKE-FREE FUTURE 8
Slide 9: Scientific Framework
SCIENTIFIC FRAMEWORK CONSTITUENT INDIVIDUAL RISK POPULATION HARM REDUCTION REDUCTION REDUCTION Risks and Product Chemical Toxicology Studies in Perception Benefits to Design and and Physical and Risk Adult Human and Behavior Health of the Control Characterization Assessment Subjects Assessment Popul
Slide 10: E-Cigarette survey section
Ati Can Sens Unctage Tobacco Use Suv (UTUS) Verse: 20 E-CIGARETTE SECTION (CONTINUED) 12a," (11 Q0a i 1-3] During tne past 30 days, what o-cigare apply) 7 (splay brand ist) ’ Altria FB aia bu 4 sMoK ft Cot Snes Eonemoke 2 sme Science uu 3 Stern ware 3 NUOY -6 Some other brand not Our Approach Our Sc
Slide 11: Altria's Vision by 2030
Our Approach Our Sclence Product Platforms Communications & Engagement Library Altria's Vision by 2030 Responsibly lead the transition of adult smokers. to a smoke-free future. Movang beyond smokang Shy Atcria 11
Slide 12: Proposed Product Standards for Reduced Risk
PROPOSED PRODUCT ORAL TOBACCO ELECTRONIC HEATED DERIVED NICOTINE DELIVERY TOBACCO STANDARDS FOR NICOTINE SYSTEMS PRODUCTS REDUCED RISK TOBACCO PRODUCTS IN THE UNITED STATES Nicotine/Nicotine Sales Other Ingredients and/or Product Prepared by Altria Client Services, LLC March 16, 2021 Components Cons
Slide 13: Tuesday Morning, August 31, 2021
TUESDAY MORNING, August 31, 2021 8:30 AM 13
Slide 14: Products must be appealing to transition smokers
The only products that will successfully transition adult smokers who can’t or won’t quit to a smoke free alternative are ones that are appealing and that they actually want to use 14
Slide 15: FDA may withdraw a marketing order
The FDA may withdraw a marketing order if it, among other reasons, determines that the continued marketing of a product is no longer appropriate for the protection of the public health, such as if there is an uptake of the product by youth. https://www.fda.gov/news-events/press-announcements/fda-per
Slide 16: Menthol versions prohibited in some stores
Despite FDA’s conclusions manufacturers are prohibited from offering menthol versions of these products in some stores, undermining harm reduction efforts https://www.fda.gov/news-events/press-announcements/fda-permits-sale-iqos- tobacco-heating-system-through-premarket-tobacco-product-application-p
Slide 17: Nicotine Misperceptions
NICOTINE MISPERCEPTIONS Could result in smokers rejecting smoke-free alternatives 73 CONSUMERS % > 80 PHYSICIANS % INCORRECTLY believed, or were “Strongly agreed” nicotine directly unsure, that nicotine was the main contributes to the development of cause of cancer in cigarettes cardiovascular disea
Slide 18: Nicotine not directly responsible for tobacco-caused disease
Nicotine, though not benign, is not directly responsible for the tobacco-caused cancer, lung disease, and heart disease that kill hundreds of thousands of Americans each year – Former FDA Commissioner Gottlieb and CTP Director Zeller https://www.fda.gov/tobacco-products/health-information/nicotine-a
Slide 19: Factual scientific information must be available to consumers
Factual scientific information from trusted sources must be made available to adult tobacco consumers 19
Slide 20: Equitable Harm Reduction
EQUITABLE HARM REDUCTION 20
Slide 21: Earning trust through the strength of our science
We aim to continue to earn trust through the strength of our science and demonstrated commitment to adult smoker transition to smoke-free products 21
Slide 22: Noncombustible Future
33,000,000+ US adult smokers Responsibly lead the transition of adult smokers to a NONCOMBUSTIBLE FUTURE Source: Altria Client Services LLC Adult Tobacco Consumer Tracker (ALCS ATCT) Age 21 or older 22
Altria Group — 74th Tobacco Science Research Conference 2021 on 6ix